{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["64(4)"],"submitter":["Roman-Montes CM"],"pubmed_abstract":["<h4>Objective</h4>Our aim was to evaluate the performance of two galactomannan (GM) assays (Platelia Aspergillus EIA, Bio-Rad<sup>®</sup> , and Aspergillus GM LFA, IMMY<sup>®</sup> ) in tracheal aspirate (TA) samples of consecutive critically ill patients with COVID-19.<h4>Methods</h4>We included critically ill patients, performed GM-EIA and GM-Lateral Flow Assay (GM-LFA) in TA and followed them until development of COVID-19-associated pulmonary aspergillosis (CAPA) or alternate diagnosis. CAPA was defined according to the modified AspICU criteria in patients with SARS-CoV-2 infection. We estimated sensitivity, specificity, positive and negative predictive values for GM-EIA, GM-LFA, the combination of both or either positive results for GM-EIA and GM-LFA. We explored accuracy using different breakpoints, through ROC analysis and Youden index to identify the optimal cut-offs. We described antifungal treatment and 30-day mortality.<h4>Results</h4>We identified 14/144 (9.7%) patients with CAPA, mean age was 50.35 (SD 11.9), the median time from admission to CAPA was 8 days; 28.5% received tocilizumab and 30-day mortality was 57%. ROC analysis and Youden index identified 2.0 OD as the best cut-off, resulting in sensitivity and specificity of 57.1% and 81.5% for GM-EIA and 60% and 72.6% for GM-LFA, respectively.<h4>Conclusions</h4>The diagnostic performance of GM in tracheal aspirates improved after using a cut-off of 2 OD. Although bronchoalveolar lavage testing is the ideal test, centres with limited access to bronchoscopy may consider this approach to identify or rule out CAPA."],"journal":["Mycoses"],"pagination":["364-371"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7753336"],"repository":["biostudies-literature"],"pubmed_title":["Accuracy of galactomannan testing on tracheal aspirates in COVID-19-associated pulmonary aspergillosis."],"pmcid":["PMC7753336"],"pubmed_authors":["Martinez-Gamboa A","Roman-Montes CM","Rangel-Cordero A","Gonzalez-Lara MF","Cervantes-Sanchez A","Ponce-de-Leon A","Sifuentes-Osornio J","Diaz-Lomeli P"],"additional_accession":[]},"is_claimable":false,"name":"Accuracy of galactomannan testing on tracheal aspirates in COVID-19-associated pulmonary aspergillosis.","description":"<h4>Objective</h4>Our aim was to evaluate the performance of two galactomannan (GM) assays (Platelia Aspergillus EIA, Bio-Rad<sup>®</sup> , and Aspergillus GM LFA, IMMY<sup>®</sup> ) in tracheal aspirate (TA) samples of consecutive critically ill patients with COVID-19.<h4>Methods</h4>We included critically ill patients, performed GM-EIA and GM-Lateral Flow Assay (GM-LFA) in TA and followed them until development of COVID-19-associated pulmonary aspergillosis (CAPA) or alternate diagnosis. CAPA was defined according to the modified AspICU criteria in patients with SARS-CoV-2 infection. We estimated sensitivity, specificity, positive and negative predictive values for GM-EIA, GM-LFA, the combination of both or either positive results for GM-EIA and GM-LFA. We explored accuracy using different breakpoints, through ROC analysis and Youden index to identify the optimal cut-offs. We described antifungal treatment and 30-day mortality.<h4>Results</h4>We identified 14/144 (9.7%) patients with CAPA, mean age was 50.35 (SD 11.9), the median time from admission to CAPA was 8 days; 28.5% received tocilizumab and 30-day mortality was 57%. ROC analysis and Youden index identified 2.0 OD as the best cut-off, resulting in sensitivity and specificity of 57.1% and 81.5% for GM-EIA and 60% and 72.6% for GM-LFA, respectively.<h4>Conclusions</h4>The diagnostic performance of GM in tracheal aspirates improved after using a cut-off of 2 OD. Although bronchoalveolar lavage testing is the ideal test, centres with limited access to bronchoscopy may consider this approach to identify or rule out CAPA.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2025-04-22T06:53:19.893Z","creation":"2025-04-05T21:54:28.115Z"},"accession":"S-EPMC7753336","cross_references":{"pubmed":["33217784"],"doi":["10.1111/myc.13216"]}}